Precigen, Inc. (PGEN)
NASDAQ:PGEN
Want to see PGEN full AI Analyst Report?
Top Page
Precigen
(NASDAQ:PGEN)
Select Model
Select Model
Rating:56Neutral
Price Target:
$4.50
▲(13.07% Upside)
Action:Reiterated
Date:05/15/26
The score is mainly constrained by weak financial fundamentals (ongoing losses, heavy cash burn, and higher leverage), despite strong technical momentum and a constructive earnings-call backdrop driven by PAPZIMEOS launch acceleration and improving cash-use expectations. Valuation signals are limited based on the provided P/E and dividend data.
Positive Factors
Commercial Launch Momentum
A rapid first-quarter revenue ramp demonstrates early commercial traction and real-world demand for PAPZIMEOS, validating go-to-market execution. Durable adoption in initial quarters increases the chance of repeatable sales, supports future cash generation, and de-risks the company’s shift from R&D to commercial-stage operations.
Negative Factors
Profitability and Low Gross Margin
A low gross margin limits the portion of revenue that converts to operating profit, meaning even rising sales may not quickly translate to sustainable earnings. Persistent operating and net losses indicate the business still needs scale or margin improvement to achieve durable profitability, heightening execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial Launch Momentum
A rapid first-quarter revenue ramp demonstrates early commercial traction and real-world demand for PAPZIMEOS, validating go-to-market execution. Durable adoption in initial quarters increases the chance of repeatable sales, supports future cash generation, and de-risks the company’s shift from R&D to commercial-stage operations.
Read all positive factors
Precigen (PGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.45B
Dividend YieldN/A
Average Volume (3M)3.26M
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth652.08%
EPS Growth-116.59%
CountryUS
Employees143
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.28
Shares Outstanding356,511,000
10 Day Avg. Volume4,125,465
30 Day Avg. Volume3,263,194
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.18
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue42.43
Enterprise Value/Gross Profit56.10
Enterprise Value/Ebitda-15.53
Forecast
1Y Price Target
$11.00Price Target Upside176.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$115.44M
Precigen Business Overview & Revenue Model
Company Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive a...
How the Company Makes Money
Precigen’s revenue is primarily generated through (1) collaboration and licensing arrangements and (2) product-related revenue if/when any therapeutic candidates are approved and commercialized. For collaboration and licensing, the company can ear...
Precigen Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum for PAPZIMEOS with a rapid revenue ramp, broad payer coverage, expert endorsement, and promising clinical durability data — all signaling an impactful product launch. The company also faces near-term operational challenges including elevated quarter cash burn, increased SG&A tied to commercialization, timing of cash collections, and limited disclosure of granular conversion metrics. Management expects cash consumption to moderate in Q2 and projects runway to cash-flow breakeven by end-2026, which, together with the strong launch indicators, supports a constructive outlook.Positive Updates
Strong Commercial Launch and Revenue Acceleration
PAPZIMEOS net product revenue for Q1 2026 (first full quarter) was $21.6 million, up from $3.4 million in Q4 2025 (≈+535% quarter-over-quarter), contributing to total revenue of $23.3 million for the quarter.
Negative Updates
High Quarter Cash Usage
Cash used in operations for Q1 was $43.8 million, which is sizable; management noted $13 million of cash outflows in Q1 are non-recurring but the quarter still reflects elevated cash consumption. They expect significantly lower cash use in Q2.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Commercial Launch and Revenue Acceleration
PAPZIMEOS net product revenue for Q1 2026 (first full quarter) was $21.6 million, up from $3.4 million in Q4 2025 (≈+535% quarter-over-quarter), contributing to total revenue of $23.3 million for the quarter.
Read all positive updates
Company Guidance
The company reiterated that PAPZIMEOS launch momentum should continue into Q2 and beyond, highlighting Q1 2026 net product revenue of $21.6M (up from $3.4M in Q4 2025) and total revenue of $23.3M, while noting operating loss of $6.0M and net loss of $7.9M ($0.02 per share); other Q1s: R&D $5.6M (down $4.8M y/y), SG&A $21.0M (up $8.7M), cash used in operations $43.8M (including $13M of one‑time outflows), and cash/cash equivalents/investments of $56.7M. Management said they expect Q2 cash used in operations to be “significantly lower,” they are not providing formal revenue guidance this quarter but will report Q2 results in August, and they forecast existing cash plus collection of PAPZIMEOS receivables will fund operations to cash‑flow breakeven by the end of 2026 without needing capital markets. Other operational metrics cited: ~400 patients registered in the Precigen hub (25% in community), estimated 297M lives covered (~>90% of insured U.S. lives), permanent J‑code effective April 1, median follow‑up for durability ~3 years, pediatric trial planned to start in Q4 2026, and redosing and PRGN‑2009 updates expected later in the year.Precigen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.59M | 9.68M | 3.92M | 6.22M | 26.91M | 14.27M |
| Gross Profit | 23.90M | 3.59M | -342.00K | 106.00K | 20.57M | -39.41M |
| EBITDA | -86.33M | -103.40M | -123.50M | -89.23M | -62.43M | -77.64M |
| Net Income | -204.42M | -250.64M | -126.23M | -95.90M | 28.32M | -92.17M |
Balance Sheet | ||||||
| Total Assets | 138.63M | 156.62M | 145.27M | 151.04M | 215.98M | 359.86M |
| Cash, Cash Equivalents and Short-Term Investments | 56.25M | 97.86M | 97.91M | 62.85M | 55.95M | 108.66M |
| Total Debt | 98.25M | 5.12M | 5.50M | 7.10M | 51.42M | 190.07M |
| Total Liabilities | 118.39M | 135.71M | 106.75M | 32.55M | 89.72M | 252.51M |
| Stockholders Equity | 20.23M | 20.91M | 38.51M | 118.50M | 126.26M | 107.35M |
Cash Flow | ||||||
| Free Cash Flow | -117.57M | -89.83M | -76.76M | -68.47M | -69.97M | -63.02M |
| Operating Cash Flow | -115.33M | -87.83M | -68.17M | -66.93M | -65.05M | -55.77M |
| Investing Cash Flow | 25.89M | -1.53M | -20.71M | -3.09M | 226.42M | -74.54M |
| Financing Cash Flow | 90.84M | 90.05M | 110.58M | 29.59M | -155.29M | 121.19M |
Precigen Technical Analysis
Neutral
3.98
Price Trends
3.90
Positive
4.12
Positive
3.90
Positive
Market Momentum
0.08
Positive
50.79
Neutral
27.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Neutral. The current price of 3.98 is below the 20-day moving average (MA) of 4.16, above the 50-day MA of 3.90, and above the 200-day MA of 3.90, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 50.79 is Neutral, neither overbought nor oversold. The STOCH value of 27.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PGEN.
Precigen Risk Analysis
Precigen disclosed 67 risk factors in its most recent earnings report. Precigen reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precigen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $534.72M | -13.50 | 12.86% | ― | 10.51% | -23.96% | |
64 Neutral | $8.94B | -25.13 | -43.02% | ― | -100.00% | -24.90% | |
56 Neutral | $1.45B | -38.19 | -1768.51% | ― | 652.08% | -116.59% | |
55 Neutral | $1.23B | -13.91 | -56.41% | ― | -31.58% | -27.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.25B | -11.49 | -51.15% | ― | -63.29% | 25.39% | |
46 Neutral | $820.89M | -9.34 | -35.33% | ― | ― | 23.91% |
* Healthcare Sector Average
PGEN
Precigen
4.16
2.75
195.04%
MDXG
MiMedx Group
3.64
-3.53
-49.23%
WVE
Wave Life Sciences
6.14
-0.40
-6.12%
ORIC
Oric Pharmaceuticals
7.97
2.30
40.56%
IMNM
Immunome
19.66
11.10
129.67%
PRAX
Praxis Precision Medicines
320.61
280.91
707.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.